EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AVANIR Pharmaceuticals's enterprise value is €2,686.27 Mil.
AVANIR Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2014 was €85.46 Mil. Therefore, AVANIR Pharmaceuticals's EV-to-Revenue for today is 31.43.
The historical rank and industry rank for AVANIR Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
FRA:AV2B'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 26.19
FRA:AV2B's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.415
vs FRA:AV2B: 26.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVANIR Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVANIR Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where AVANIR Pharmaceuticals's EV-to-Revenue falls into.
AVANIR Pharmaceuticals's current Enterprise Value is €2,686.27 Mil.
AVANIR Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €85.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals's share price for today is €14.37.
AVANIR Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your 